MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Moderna, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$226.89+8.88 (+4.07%)
Close on Oct 19, 2026
- Market cap
- $90.30B
- P/E (TTM)
- –
- Dividend yield
- –
Moderna statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Moderna | Industry median |
|---|---|---|
| Market Cap | $90.58B | $197.05M |
| Enterprise Value | $86.04B | $106.56M |
| PS Ratio | 40.66 | 3.93 |
| PB Ratio | 13.40 | 2.14 |
| P/TBV Ratio | 13.72 | 2.46 |
Enterprise value
| Measure | Moderna | Industry median |
|---|---|---|
| EV / Sales | 38.62 | 2.69 |
Income (trailing twelve months)
| Measure | Moderna | Industry median |
|---|---|---|
| Revenue | $2.23B | $57.94M |
| Gross Profit | $521.00M | $90.47M |
| Operating Income | -$3.32B | -$21.44M |
| Pretax Income | -$3.09B | -$14.45M |
| Net Income | -$3.15B | -$22.46M |
| EBITDA | -$3.09B | -$16.91M |
| EPS (Diluted) | -$7.99 | -$0.83 |
Margins
| Measure | Moderna | Industry median |
|---|---|---|
| Gross Margin | 23.4% | 52.3% |
| Operating Margin | -149.0% | -44.5% |
| Pretax Margin | -138.6% | -13.0% |
| Profit Margin | -141.4% | -39.2% |
| EBITDA Margin | -138.7% | -31.3% |
| FCF Margin | -55.8% | -8.85% |
Returns
| Measure | Moderna | Industry median |
|---|---|---|
| Return on Equity (ROE) | -39.0% | -53.1% |
| Return on Assets (ROA) | -27.4% | -41.0% |
| Return on Invested Capital (ROIC) | -80.9% | -32.0% |
| Return on Capital Employed (ROCE) | -39.4% | -37.8% |
Growth
| Measure | Moderna | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -27.6% | 6.01% |
| Revenue Growth (3Y CAGR) | -53.4% | 2.25% |
| Revenue Growth (5Y CAGR) | 19.3% | 6.42% |
Balance sheet
| Measure | Moderna | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $5.14B | $62.42M |
| Total Debt | $591.00M | $120.13M |
| Net Cash (Debt) | $4.55B | $15.68M |
| Net Cash Per Share | $11.39 | $0.65 |
| Equity (Book Value) | $6.76B | $48.79M |
| Book Value Per Share | $16.93 | $1.36 |
| Tangible Book Value | $6.60B | $23.06M |
| Working Capital | $3.28B | $75.77M |
Financial position
| Measure | Moderna | Industry median |
|---|---|---|
| Current Ratio | 2.29 | 3.30 |
| Quick Ratio | 2.03 | 2.39 |
| Debt / Equity | 0.09 | 0.51 |
Cash flow (trailing twelve months)
| Measure | Moderna | Industry median |
|---|---|---|
| Operating Cash Flow | -$1.07B | -$12.35M |
| Capital Expenditures | -$171.00M | -$1.06M |
| Free Cash Flow | -$1.24B | -$20.28M |
| FCF Per Share | -$3.12 | -$0.41 |
Efficiency
| Measure | Moderna | Industry median |
|---|---|---|
| Asset Turnover | 0.19 | 0.38 |
| Inventory Turnover | 6.57 | 2.67 |
| Revenue Per Employee | $474.04K | $398.96K |
| Profits Per Employee | -$670.43K | -$732.08K |
| Employee Count | 4,700 | 73 |
Dividends and yields
| Measure | Moderna | Industry median |
|---|---|---|
| Earnings Yield | -3.48% | -21.2% |
| FCF Yield | -1.37% | -7.64% |
Shares
| Measure | Moderna | Industry median |
|---|---|---|
| Shares Outstanding | 399,236,000 | 59,128,900 |
| Shares Change (YoY) | 0.96% | 11.1% |
| Shares Change (QoQ) | 0.50% | 0.54% |
| Float | 376,864,000 | 48,744,500 |
| Shares Held by Insiders | 5.60% | 11.8% |
| Shares Held by Institutions | 79.9% | 59.4% |
Taxes
| Measure | Moderna | Industry median |
|---|---|---|
| Income Tax | $64.00M | $91.50K |
Scores
| Measure | Moderna | Industry median |
|---|---|---|
| Altman Z-Score | 13.15 | 0.10 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Moderna's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.